Loading data for OCS — first visit, this takes a few seconds.

알림

Oculis Holding AG (OCS)

NasdaqGM: OCS · 실시간 가격 · USD

12.94

+0.12 (0.94%)

종가 기준: Aug 19, 2026, 8:00 PM

13.57

+0.00%

애프터마켓: 4:00 PM

0.94% (1D)

데이터 없음

매수호가	8.8
시가총액	753.51M
매출 (ttm)	1.17M
순이익 (ttm)	-79.19M
베타	0.23
EPS (ttm)	-1.7
P/E (ttm)	n/a
선행 P/E	-6.68
P/B (ttm)	3.10
P/S (ttm)	642.38
Earnings Date	Nov 5, 2026

매도호가	15.29
거래량	123,685
평균 거래량 (20일)	668,620
시가	12.84
전일 종가	12.82
일중 범위	12.52 - 13.09
52주 범위	10.52 - 34.48
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

OCS 소개

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the trea...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 18, 2021

직원 수 60

상장 거래소 NasdaqGM

티커 OCS

웹사이트 https://oculis.com

전체 기업 정보

재무 실적

2025년 Oculis의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -98.96M로, 15.37% 증가했습니다.

재무제표

어닝 서프라이즈

Oculis가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.16 예상치 상회 0.22, 및 67.35% 전년 대비 성장.

다음 실적 발표

Oculis Holding AG의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · MT Newswires

Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com

1주 전 · Zacks

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2개월 전 · Motley Fool

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.

2개월 전 · MarketBeat

Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals

Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug...

2 페이지 중 1

Oculis Holding AG (OCS)